INNV · InnovAge Holding Corp.
$9.13
+0.13 (+1.44%)
At close · Oct 7
Return incl. dividend (before tax)
Market Cap
$1.25B
Shares
136.45M
Volume · Oct 7
342.16K
Avg daily vol (3M)
438.38K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$9.13
Open$8.91
Day$8.91–9.20
52W close$3.99–12.11
Avg vol 30d669K
Short int1.2M · 0.9% float · 3.8d
Short vol51%
Last earningsSep 8, 2026
DataMar 2021–Oct 2026
Filing10-K · Sep 9
Up next
Next earnings call
Dec 8, 2026
Est · unconfirmed
· in 9 wks
filed Sep 9, 2026
call held Sep 8, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$989.71M
Trailing 12 months
Net income (TTM)
−$2.54M
Trailing 12 months
Revenue growth YoY
+18.3%
Year over year
Operating margin
0.3%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
4.1%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$93.27M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.4%
Year over year · more shares
Price change (1Y)
+74.8%
Trailing year
Short interest
0.9%
Latest settlement · 3.8 days to cover
AI Brief
Q4 FY26 earnings call · Sep 8, 2026
Q4 FY26
TL;DR. InnovAge reported FY26 revenue of $989.7M (up 15.9%) and adjusted EBITDA of $94.6M (up ~175%), and issued FY27 guidance of $1.05–$1.085B revenue and $105–$115M adjusted EBITDA, while ongoing legal accruals and a more moderated rate environment temper the outlook.
Bullish
- + FY26 revenue grew 15.9% to $989.7M and adjusted EBITDA grew ~175% to $94.6M with margin expanding to 9.6%
- + Center-level contribution margin expanded 500 bps to 23.0% of revenue in FY26
- + FY27 adjusted EBITDA guidance of $105–$115M implies further margin expansion toward the 10%+ long-term target
Bearish
- − FY26 net loss of $0.7M was driven by a $36.8M increase in litigation and settlement expenses
- − FY27 revenue growth of ~6–10% slows materially versus FY26's 15.9% as rate environment moderates
- − California and Colorado rate-setting processes remain unresolved, creating rate uncertainty for ~70% of census
- − Cost of care per participant rose 16.1% in FY26 on higher wages, contract services, fleet, and supplies
- − V28 risk adjustment transition to 50/50 blend will pressure Medicare rate tailwind in FY27
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 15.1 · calm
Equity put/call 0.63
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+4%
above
Price vs 50-day avg
−13%
below
RSI (14)
37
neutral
MACD trend
Negative
52-week position
63%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−17%
trailing
6-month return
+9%
trailing
YTD return
+76%
this year
Relative strength
−2%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $10 › 200d $9 — 50d above 200d
Institutional flow
Accumulating
1 of 107 funds reported for Sep 30 · net +74.1K sh shares · +1 new
Insider flow
Distributing
Net -$92.5M over 90 days · 100% sells
Short interest
Rising
0.86% of float · ▲ +14.3% MoM · 3.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
107 holders — near 3-yr high, broad support
Squeeze score
52
elevated · 0–100
Fundamentals
Revenue growth
+16%
Y/Y
Gross margin
23%
expanding
EPS growth
+91%
Y/Y
Free cash flow
$50.4M
Buyback
$7.5M
authorized
Balance sheet
$49.8M
net cash
Quant / Vol
risk profile
Volatility
78%
annualized · 1-yr
Max drawdown
−33%
past year
ATR
5.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Sep 8, 2026
Total revenues
· Full Fiscal Year 2027
Initiated
$1.05B – $1.09B
prior FY $989.71M
midpoint +7.9% Y/Y
Adjusted EBITDA
· Full Fiscal Year 2027
Non-GAAP
Initiated
$105M – $115M
Prior guidance
period ended
· from the Earnings Call filed Mar 31, 2026
Total revenue
· fiscal year 2026
$950M – $975M
Adjusted EBITDA
· fiscal year 2026
$85M – $90M
De novo losses
· fiscal year 2026
$11.5M – $13.5M
Guided vs delivered
· last 4 settled
Total revenue
fiscal year 2026
guided $950M – $975M
$989.71M
Beat +2.8%
Total revenues
fiscal year 2022
guided $712M – $725M
$698.64M
Miss −2.8%
Revenues
fiscal Q4
guided $160M – $162M
$171.62M
Beat +6.6%
Revenues
full fiscal year 2021
guided $626M – $628M
$637.8M
Beat +1.7%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+4%
Bullish
Price vs 50-day avg
−13%
Bearish
RSI (14)
37
Neutral
MACD trend
Negative
Bearish
52-week position
63%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $10 › 200d $9 — 50d above 200d
Institutional flow
Accumulating
1 of 107 funds reported for Sep 30 · net +74.1K sh shares · +1 new
Insider flow
Distributing
Net -$92.5M over 90 days · 100% sells
Short interest
Rising
0.86% of float · ▲ +14.3% MoM · 3.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
107 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $4
Now $9 · 63%
Range high $12
vs 200-day avg +4%
vs 50-day avg -13%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| average participant tenure | 3.1 | fiscal year 2026 filing | — |
| average RAF score | 2.48 | fiscal year 2026 filing | — |
| centers | 20 | fiscal year ended June 30, 2026 filing | — |
| cost of care, excluding depreciation and amortization as a % of revenue | 77% | the year ended June 30, 2026 filing | — |
| I-SAT NPS score | 52 | fiscal year 2026 filing | — |
| Medicare capitation revenue concentration | 44% | fiscal year ended June 30, 2026 filing | — |
| Adjusted EBITDA non-GAAP | $94.6M | Year Ended June 30, 2026 | — |
|
|
|||
| Adjusted EBITDA margin non-GAAP | 9.6% | Year Ended June 30, 2026 | — |
| Census | 8,230 | As of June 30, 2026 | — |
| Center- Level Contribution Margin as a % of revenue non-GAAP | 23% | Year Ended June 30, 2026 | — |
|
|
|||
| Center-level Contribution Margin non-GAAP | $227.8M | Year Ended June 30, 2026 | — |
|
|
|||
| Center-level Contribution Margin as a percent of revenue non-GAAP | 23% | Year Ended June 30, 2026 | — |
| Member months | 96,050 | Year Ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
INNV
this stock
InnovAge Holding Corp.
|
$1.25B | +75.9% | +15.9% | — | 0.9% |
|
HCA
HCA Healthcare, Inc.
|
$97.43B | -5.9% | +7.1% | 15.1 | 2.9% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$27.49B | -14.9% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$20.91B | +30.8% | +0.9% | 10.0 | 2.5% |
|
EHC
Encompass Health Corp
|
$11.93B | +15.4% | +10.5% | 19.7 | 3.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| INNV | +3.8% | -17.2% | +9.1% | +3.8% | +75.9% |
| SPY | +1.9% | +1.9% | +10.8% | +1.9% | +14.0% |
| vs SPY | +1.8% | -19.2% | -1.7% | +1.8% | +61.9% |
Capital returns
Buyback programs
· 2 active
· as of Sep 26, 2024
Authorized (total)
$7.50M
Spent (derived)
—
Remaining
—
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.